patients are hospitalized for a longer period, to try to prevent readmission, further increasing healthcare costs. Therefore, it is of great importance to detect patients at low risk and understand the pathophysiology behind early readmissions. Identifying patients who may be safely discharged early because of adequate decongestion and a low risk of rehospitalization would also be of significant clinical use. Recently, several studies have shown that inadequate response to diuretic treatment is particularly related to an increased risk of early readmission after hospital discharge for acute HF. [4] [5] [6] [7] Similarly, several other studies showed hemoconcentration (ie, an increase in hemoglobin/hematocrit in response to diuretic therapy during hospital admission) is related to a lower risk of rehospitalization after an acute HF admission. [8] [9] [10] Both diuretic response and hemoconcentration provide estimates of the adequacy of decongestion during hospital admission. Therefore, this study aimed to combine both measures to improve our estimation of adequacy of decongestion and our ability to distinguish between patients at low and high risk of early rehospitalization for acute HF.
Methods

Study Design and Procedures
The design and main results of Placebo-Controlled Randomized Study of the Selective Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) and Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) have been published previously. 11, 12 In brief, PROTECT and EVEREST were both multinational, prospective, multicentre, randomized, doubleblind, placebo-controlled trials in patients with acute HF. PROTECT, which investigated the effects of rolofylline, was a trial with neutral results and enrolled 2033 adult patients with mild-to-moderate renal dysfunction and acute HF. The EVEREST trial enrolled 4133 patients and investigated the effect of oral tolvaptan on clinical outcomes in patients a reduced ejection fraction hospitalized for worsening HF. All patients provided informed written informed consent, and both trials were conducted in accordance with the declaration of Helsinki and approved by local ethics committees at all participating sites.
In PROTECT, HF signs and symptoms, serum creatinine and blood urea nitrogen were assessed daily until discharge or day 6, and on days 7 and 14. Body weight was assessed from baseline through day 4. Other biochemical and hematologic markers were measured at least at baseline and on days 2, 7, and 14. In EVEREST, biochemical and hematologic markers were assessed a baseline and discharge or day 7, and weight data were collected through discharge. Diuretic administration during hospitalization was recorded in both the studies. Glomerular filtration rate was calculated with the simplified modification of diet in renal disease equation.
Diuretic Response and Hemoconcentration
Diuretic response was defined as weight change on day 4 from baseline per 40 mg of furosemide or equivalent administered from baseline to day 3. Loop diuretics other than furosemide were converted into equivalent doses as follows: 40-mg furosemide, 1-mg bumetanide, and 20-mg torsemide. Half of the oral dose was used to adjust for biological availability. 5 Hemoconcentration was defined as change in hemoglobin on hospital day 7 or discharge from baseline, whichever came first. 10
Study Population
Initial analyses were performed in PROTECT and validated in EVEREST in patients with no missing data on the primary variables of interest. In EVEREST we excluded 548 patients who did not receive loop diuretics. Patients with missing data for diuretic response (PROTECT n=278 and EVEREST n=1421), >20 kg weight loss (PROTECT=3 and EVEREST n=0), 5 who underwent dialysis through day 4 (PROTECT n=7 and EVEREST not recorded) or missing data on hemoconcentration (PROTECT n=565 and EVEREST n=388) were excluded, resulting in a study population of 1180 patients for PROTECT and 1776 patients for EVEREST. The included populations did not differ greatly from the excluded populations (Tables I  and II in the Data Supplement) .
End Points
The primary end points for this study were HF rehospitalization or renal or cardiovascular rehospitalization within 60 days for PROTECT and HF rehospitalization or cardiovascular rehospitalization within 60 days for EVEREST. Associations with mortality through 180 days were also examined in both populations. End points were adjudicated by independent clinical end point committees for each trial.
Statistical Analysis
Initial analyses were performed in PROTECT and validated in EVEREST. All analyses were performed in the intention to treat population, checking for effects of and interactions with study treatment. Continuous data are summarized as mean±SD or median (firstthird quartiles) depending on distribution. Student t test or ANOVA (normal distribution) and Wilcoxon or Kruskall-Wallis (skewed distribution) tests were used for group comparisons as appropriate. Differences in proportions were assessed using χ 2 tests. Trends across categories were tested using nonparametric tests for trend for categorical variables and generalized linear models with polynomial contrasts for continuous variables. Risk of adverse outcome per tertile of diuretic response was assessed using Kaplan-Meier estimates and log-rank tests. Only complete cases were used for all primary analyses; no imputations were performed.
Cox proportional hazards regression was used to examine associations with the end points. Multivariable models were adjusted for a previously published model developed in PROTECT that includes age, previous HF hospitalization, edema, systolic blood pressure, serum sodium, blood urea nitrogen, serum creatinine and albumin. 13 In addition to this, we also adjusted for hemoglobin and study treatment. Covariates were transformed as appropriate, with multiple fractional polynomials used to assess the linearity of associations.
The added value of diuretic response and hemoconcentration for estimating the risk of rehospitalization was assessed by examining gain in Harrell C-index (a measure of model discrimination and higher values are better), using likelihood ratio tests for nested survival models, and assessment of continuous net reclassification improvement (a category-independent measure quantifying the degree of improvement in model-based risk estimates obtained by adding a marker to a model). Tests are 2-tailed, and an unadjusted P value <0.05 was considered statistically significant. All analyses were performed using R: A Language and Environment for Statistical Computing, version 3.1.3 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Baseline Characteristics
Baseline characteristics for both PROTECT and EVEREST populations are presented in Table 1 . Patients in PROTECT were more often female, were older, and comorbidities were more common than in EVEREST. Patients in PROTECT also showed more signs of congestion, such as edema, orthopnea, and elevated jugular venous pressure. Renal function was worse, hemoglobin levels were lower, and B-type natriuretic peptide levels were higher. Median diuretic response was Baseline characteristics for the 2 populations, stratified by tertile of diuretic response, are presented in Table 2 (PROTECT) and the PROTECT, patients with poor diuretic response were more likely to have renal impairment, and they had signs of more advanced HF, including more frequent device therapy, similar to earlier findings. 5 Similar patterns were seen in EVEREST, although in contrast with PROTECT, some comorbiditiessuch as diabetes mellitus and myocardial infarction-were not strongly associated with diuretic response. Interestingly, B-type natriuretic peptide levels at admission were not associated with diuretic response in either population. Hemoconcentration was not strongly associated with clinical characteristics or medical history in either trial population (P for trend=n.s. across tertiles). Patients who hemoconcentrated more did have better renal function, lower blood urea nitrogen levels, and lower hemoglobin at baseline (Tables III  and IV in the Data Supplement).
Outcomes
Clinical outcomes for PROTECT and EVEREST are presented in Tables 2 and 3 . Rates for all rehospitalization end points and mortality were numerically higher in PROTECT compared with EVEREST. In both cohorts, however, a significant trend over tertiles of diuretic response showed higher incidences of adverse outcomes in patients with a poor diuretic response. Both diuretic dose and weight loss were higher in PROTECT.
In this subset of PROTECT, diuretic response was associated with both rehospitalization end points and mortality: 60-day HF rehospitalization: HR, In EVEREST, hemoconcentration did not multivariably predict any of the outcomes (all P=n.s.). Study treatment did not show a significant effect on outcome or interactions with either diuretic response or hemoconcentration in any of the models. Table V in the Data Supplement displays the gain in prediction (C-index) and improvement in reclassification over the base clinical model in PROTECT and EVEREST. This shows a statistically significant, although minor increase in C-statistic and improvement in reclassification for 60-day HF rehospitalization for PROTECT in particular; patterns are similar in both populations, although nonsignificant in EVEREST. To examine whether combining hemoconcentration and diuretic response could provide better risk stratification, we classified patients into groups, based on a diuretic response above (poor response) or below (good response) the median, and hemoconcentration above (good hemoconcentration) or below (poor hemoconcentration) the median. In both cohorts, patients with a good diuretic response and poor hemoconcentration did not differ significantly in terms of clinical characteristics to patients with a good diuretic response and good hemoconcentration. Figure 1A (PROTECT) and Figure 1B (EVEREST) displays the Kaplan-Meier curves for these groups, illustrating that patients who hemoconcentrate well in the presence of good diuretic response are at markedly lower risk of HF rehospitalization. Similarly, Figure 2A (PROTECT) and Figure 2B (EVEREST) illustrates the lower risk of renal and cardiovascular rehospitalization for patients with a good diuretic response and good hemoconcentration. Table VI in the Data Supplement shows the number of events and positive and negative predictive value of the 4 groups based on good/poor diuretic response and good/poor hemoconcentration. Table 4 shows the significant additive value of hemoconcentration in the presence of good diuretic response to identify patients at low risk of HF hospitalization. This pattern remained after multivariable adjustment. There was no significant interaction between hemoconcentration and diuretic response. Patients with hemoconcentration and diuretic response above the median were about half as likely to be readmitted for HF compared with those without both of these responses to therapy (PROTECT: 0.41 (0.24-0.70), P=0.001 and EVEREST: 0.53 (0.34-0.84), P=0.007). The increased risk of all other groups (good diuretic response, poor hemoconcentration, etc) compared with the patients with good diuretic response and hemoconcentration is shown in Table 5 .
Discussion
The presence of hemoconcentration in addition to good diuretic response allows for identification of patients at significantly lower risk of rehospitalization for acute HF. Thus, examining both decongestive markers may provide an easy accessible and relevant tool for clinicians to identify patients at particularly low risk of rehospitalization, with the potential for easing the burden on already overburdened healthcare systems. Rehospitalization rates after an admission for acute HF are as high as 40% within 1 year, and 25% of patients are readmitted within 30 days. 14, 15 This is a major problem and places an enormous strain on our healthcare system and costs. Identification of low-risk patients is important, as early discharge and less frequent follow-up may be safe in this group of patients. Therefore, clinically applicable tools that can be used to identify low-risk patients are sorely needed. Prediction of HF rehospitalization, however, even in the short term, remains a challenge. Using variables previously identified as strong outcome predictors in the PROTECT trial, reflecting a variety of important pathophysiological mechanisms (including renal dysfunction, low arterial blood pressure, serum albumin and sodium), only achieved modest accuracy, with C-indices around 0.70. 13 Diuretic response, a recently defined measure of decongestion, has been identified as a marker for prognosis, particularly short-term HF rehospitalization. 5, 6 Diuretic response is a dynamic marker that encompasses complex mechanisms involved in response to diuretics, such as absorption, pharmacodynamics, and renin-angiotensin system activation. 16 Hemoconcentration however is also a marker of decongestion and may be seen as a correction of volume overload, in which diuretics restore euvolemia and hemoglobin levels rise as a result. Hemoconcentration has also been shown to be related to a lower risk of HF rehospitalization. 10 As both diuretic response and hemoconcentration assess decongestion, we hypothesized that the combination of both provides additive value in predicting HF rehospitalization risk, which we initially analyzed in PROTECT and validated in EVEREST. In both populations, we found that patients who exhibited a good diuretic response and hemoconcentrated were at significantly lower risk of rehospitalization for HF. Although the value of adding diuretic response and hemoconcentration to an established multivariable prediction model was limited, in patients with a good diuretic response, further assessment of hemoconcentration enables the clinician to identify a low-risk patient. This combination suggests a profile of volume overload with an excellent response to therapy, thus achieving euvolemia. In contrast, poor hemoconcentration in patients with good diuretic response may reflect true volume overload with less efficient decongestion than suggested by weight loss. The patients with good diuretic response and hemoconcentration have a 50% lower risk of being rehospitalized after discharge, and therefore shorter hospital stay, and maybe even less frequent follow-up may be safe in this patient group. Both diuretic response and hemoconcentration are easily calculated using data collected during routine care, and they are more accessible and applicable than elaborate risk models. For a clinician, evaluation of both diuretic response and hemoconcentration provides a simple assessment of risk of rehospitalization and may be used to tailor a patient's care. For instance, in the case of an acute HF patient with favorable diuretic response, in which the clinician contemplates discharge, consequent assessment of hemoconcentration may help guide his decision. In the presence of hemoconcentration, this patient can be relatively safely discharged, with a low risk of HF rehospitalization. However, the absence of hemoconcentration may trigger the clinician to re-evaluate his decision, and assess signs and symptoms again, and for instance prolong diuretic treatment for a while longer.
Overall, the associations were stronger in PROTECT than in EVEREST. There are several potential explanations. First, patients in PROTECT seem to have been sicker-older, more comorbidities, more severe renal dysfunction, higher B-type natriuretic peptide levels, and more signs of fluid overload. They also received more diuretics and lost more weight, lending support to this hypothesis. Finally, diuretic response was slightly better in PROTECT than in EVEREST.
Limitations
This study is a post hoc analysis of 2 large randomized clinical trials, with all limitations as such. In addition, the variables were only available in a subset of both the trials; we therefore cannot rule out that the associations may be biased in this selected subgroup. Further validation of the combination of this metric in registries or beyond will have to show whether these results are translatable to real-world clinical care. However, we confirmed our findings in EVEREST, thus confirming the consistency of our results in another acute HF data set. Unfortunately, our findings could not be fully replicated in EVEREST, possibly because of the slightly different HF cohort enrolled in EVEREST compared with PROTECT. We 17 In addition, a slight increase in hemoglobin may not reflect volume shifts but could also be a result of biological variation or the margin of error of the laboratory assessment. Also the underlying pathophysiology may vary. We were not able to adjust for all known predictors of adverse outcome in acute HF, as for instance N-terminal pro-B-type natriuretic peptide was only available in a small subset. Therefore, to establish true independent value of diuretic response and hemoconcentration additional studies are required. Finally, hyperglycemia because of ineffective diabetes mellitus treatment may have influenced fluid shifts; unfortunately we did not have appropriate data, such as medication for diabetes mellitus or hemoglobin A1c, available to fully elucidate this. 
CLINICAL PERSPECTIVE
Early readmission after a hospitalization for acute heart failure is a significant problem for patients and our healthcare systems. It is therefore of great importance to be able to identify patients at low risk of readmission. Given that a good decongestive response, assessed by either diuretic response or hemoconcentration, has been associated with a low risk of rehospitalization, we hypothesized that a combination of these 2 measures of decongestion should improve our estimation of adequacy of decongestion and our ability to distinguish between patients at low and high risk of early rehospitalization for acute heart failure. We performed initial analysis in 1180 patients enrolled in the Placebo-Controlled Randomized Study of the Selective Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) trial and validated our findings in 1776 patients enrolled in the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) trial. Patients with both a favorable diuretic response and a hemoconcentration had a markedly lower risk of rehospitalization in both the cohorts. Although additional validation may be required, these findings suggest that patients at low risk of early rehospitalization after an admission for acute heart failure can be identified by assessing diuretic response and hemoconcentration. Examining both decongestive markers may provide clinicians with an easily accessible and relevant tool to identify low-risk patients and to adjust treatment accordingly. 
